MA39289A - Pharmaceutical formulations of vilanterol - Google Patents

Pharmaceutical formulations of vilanterol

Info

Publication number
MA39289A
MA39289A MA039289A MA39289A MA39289A MA 39289 A MA39289 A MA 39289A MA 039289 A MA039289 A MA 039289A MA 39289 A MA39289 A MA 39289A MA 39289 A MA39289 A MA 39289A
Authority
MA
Morocco
Prior art keywords
vilanterol
pharmaceutical formulations
formulation
bpco
prophylaxis
Prior art date
Application number
MA039289A
Other languages
French (fr)
Inventor
Özlem Akdas
Devrim Celik
Ali Türkyilmaz
Original Assignee
Arven Ilac Sanayi Ve Ticaret As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2014/07010A external-priority patent/TR201407010A2/en
Application filed by Arven Ilac Sanayi Ve Ticaret As filed Critical Arven Ilac Sanayi Ve Ticaret As
Publication of MA39289A publication Critical patent/MA39289A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention se rapporte à une formulation pharmaceutique pour inhalation comprenant vilanterol en tant qu'agent actif, un excipient et du stéarate de magnésium dans le traitement et la prophylaxie des maladies respiratoires telles que l'asthme, la broncho-pneumopathie chronique obstructive (bpco), ainsi qu'à un procédé pour produire ce formulation.The present invention relates to a pharmaceutical formulation for inhalation comprising vilanterol as an active agent, an excipient and magnesium stearate in the treatment and prophylaxis of respiratory diseases such as asthma, chronic obstructive pulmonary disease (bpco ), as well as a process for producing this formulation.

MA039289A 2014-06-16 2015-06-15 Pharmaceutical formulations of vilanterol MA39289A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR201406982 2014-06-16
TR201407012 2014-06-17
TR201407009 2014-06-17
TR2014/07010A TR201407010A2 (en) 2014-06-16 2014-06-17 Vilanterol formulations.

Publications (1)

Publication Number Publication Date
MA39289A true MA39289A (en) 2015-12-23

Family

ID=77631531

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039289A MA39289A (en) 2014-06-16 2015-06-15 Pharmaceutical formulations of vilanterol

Country Status (1)

Country Link
MA (1) MA39289A (en)

Similar Documents

Publication Publication Date Title
CY1123391T1 (en) (2S)-N-[(1S)-1-CYANO-2-PHYNYLATHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS INHIBITORS OF DIPEPTYLYPEPTIDASE I
MX2019003397A (en) Methods of treating mitochondrial and metabolic disorders.
BR112018010650A2 (en) prodrugs of a compound jak inhibitor for the treatment of gastrointestinal inflammatory disease
MX2014013523A (en) Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof.
BR112017010551A2 (en) compound, methods for activating soluble guanylate cyclase, for treating one or more conditions selected from a disease in a patient and for treating a disease or condition, pharmaceutical composition, use of a compound, and, medicament.
PH12017502087B1 (en) Tiotropium inhalation solution for nebulization
MA39725B1 (en) Pharmaceutical compositions of therapeutically active compounds
BR112015018168A2 (en) soft rock inhibitors
EA201800499A1 (en) THYROZINKINASE INHIBITOR FOR THE TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS, COMPOSITION, MEDICINE, SET
MX2018006247A (en) Methods for treating alzheimer's disease and related disorders.
EP4364801A3 (en) Optimised dosage of diaminophenothiazines in populations
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
EA201891931A1 (en) NEW INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE GAMMA
MA38646A1 (en) Modified release formulation for treating, e.g. Parkinson's disease and dyskinesia induced by l-dopa.
MA39447A1 (en) (s) -pirlindole or its pharmaceutically acceptable salts for use in medicine
MA39448A1 (en) (R) -pirlindole and its pharmaceutically acceptable salts for medical use
NZ708526A (en) Novel rock inhibitors
MA39288A (en) Pharmaceutical formulations comprising vilanterol
MA39289A (en) Pharmaceutical formulations of vilanterol
EA201890789A1 (en) CONTAINING ZINEOL COMPOSITION FOR THE TREATMENT OF NOSE DISEASES
MA54630B1 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases
MX2021014093A (en) Compositions and methods for treating alzheimer's disease and parkinson's disease.
Toellner et al. C38 UNDERSTANDING THERAPEUTICS IN IPF: Clinical Experience With Nintedanib For Idiopathic Pulmonary Fibrosis In 3 Uk Tertiary Interstitial Lung Disease Centres
TR201716203A1 (en) New umeclidinium formulations.
TH170136B (en) The new indasol carboxamide The process of preparing such substances; pharmaceutical preparations which contain such substances And the use of such substances In drug production